March 29th 2023
Based on results from the phase 2 KEYNOTE-158, KEYNOTE-164, and KEYNOTE-051 trials, the FDA has given full approval to pembrolizumab for patients with microsatellite instability-high or mismatch repair deficient solid tumors.
February 27th 2023
February 17th 2023
Addressing Disparities Through the Enhancing Oncology Model and the Opportunity With Medically Integrated DispensingOctober 6th 2022
CancerNetwork spoke with AmerisourceBergen's Lisa Harrison, RPh, about how the new Enhancing Oncology Model and medically integrated dispensing factor into combating health disparities.
FDA Approves Bevacizumab-adcd Biosimilar in 6 Cancer TypesOctober 2nd 2022
Based on results from a phase 3 trial, a bevacizumab biosimilar, bevacizumab-adcd, was approved by the FDA for patients with metastatic or recurrent non-squamous non–small cell lung in addition to 5 other disease types.
Early Data Show Clinical Benefit With Gavocabtagene Autoleucel in Advanced Solid TumorsOctober 1st 2022
Treatment with gavocabtagene autoleucel demonstrated efficacy and tolerability in patients with mesothelin-expressing solid tumors, according to updated data from an ongoing phase 1/2 clinical trial.
FORE8394 Granted Fast Track Designation by FDA for Cancers With Class 1/2 BRAF AlterationsSeptember 29th 2022
FORE8394, which received fast track designation by the FDA, is under ongoing evaluation in a phase 1/2a trial in patients with advanced solid and central nervous system tumors harboring BRAF alterations.
FDA Approves Sodium Thiosulfate to Decrease Cisplatin-Associated Ototoxicity in Pediatric Localized, Non-Metastatic Solid MalignanciesSeptember 21st 2022
Sodium thiosulfate, which appears to be effective in decreasing the risk for hearing loss related to treatment with cisplatin, received FDA approval in pediatric patients with localized, non-metastatic solid tumors.
Promising Efficacy Observed With Use of CAR T-Cell Therapy BNT211-01 in Advanced Solid TumorsSeptember 9th 2022
CLDN6-directed CAR T-cell therapy BNT211-01 showed clinical activity as monotherapy and in combination with a CLDN6-encoding mRNA vaccine in relapsed/refractory advanced solid tumors.
Adequate Antibody Responses Reported After COVID-19 mRNA-1273 Vaccination During Chemotherapy/Immunotherapy Treatment for Solid TumorsJuly 21st 2022
Patients with solid tumors undergoing treatments with chemotherapy, immunotherapy, or chemoimmunotherapy mounted an adequate antibody response to the mRNA-1273 COVID-19 vaccine.
From Increased Risks to Care Barriers: Experts Highlight Unique Challenges of LGBTQ+ Cancer CommunityJune 28th 2022
Key leaders in the oncology space discuss unique cancer risk factors, barriers to care, and ways in which institutions and organizations are creating more welcoming environments for individuals within the LGBTQ+ community.
Benjamin Cooper, MD, Examines Rationale Behind Combining TAK-676 With Pembrolizumab After Radiation in Select Solid TumorsJune 27th 2022
Benjamin Cooper, MD, discussed an ongoing trial examining TAK-676 in combination with pembrolizumab after radiation therapy for patients with non–small cell lung cancer, head and neck cancer, and triple-negative breast cancer.
FDA Approves FoundationOne CDx Companion Diagnostic for Entrectinib in ROS1+ NSCLC or NTRK+ Solid TumorsJune 9th 2022
FoundationOne CDx has been approved by the FDA as a companion diagnostic for entrecitinib for the treatment of ROS1 fusion–positive non–small cell cancer or NTRK fusion–positive solid cancers.